Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
0.00% $0.0300
/ 10 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 44.43 mill |
EPS: | 0.292 |
P/E: | 0.100 |
Earnings Date: | Mar 30, 2023 |
SharesOutstanding: | 1 480.93 mill |
Avg Daily Volume: | 0 mill |
RATING 2024-04-10 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0.100 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 0.100 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
$6.95 (23 058.50%) $6.92 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 0.0154 - 0.0454 ( +/- 49.34%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-07 | Sullivan Eddie Joe | Buy | 1 740 | Common Stock |
2023-11-30 | King Michael | Buy | 5 000 | Common Stock |
2023-11-29 | Reich Samuel J | Buy | 11 000 | Common Stock |
2023-11-24 | Sessa Capital (master), L.p. | Buy | 4 584 571 | Common Stock |
2023-11-24 | Sessa Capital (master), L.p. | Buy | 28 380 | Series A-2 Convertible Preferred Stock |
INSIDER POWER |
---|
67.43 |
Last 48 transactions |
Buy: 15 469 696 | Sell: 3 137 380 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.0300 (0.00% ) |
Volume | 0.0030 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.